Analyst Price Targets — DGX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 12:27 pm | — | Mizuho Securities | $235.00 | $209.32 | TheFly | Quest Diagnostics price target raised to $235 from $210 at Mizuho |
| February 11, 2026 2:11 pm | — | UBS | $210.00 | $206.73 | TheFly | Quest Diagnostics price target raised to $210 from $190 at UBS |
| February 11, 2026 1:46 pm | — | Truist Financial | $220.00 | $205.63 | TheFly | Quest Diagnostics price target raised to $220 from $205 at Truist |
| February 11, 2026 1:11 pm | Elizabeth Anderson | Evercore ISI | $220.00 | $205.43 | TheFly | Quest Diagnostics price target raised to $220 from $190 at Evercore ISI |
| February 11, 2026 11:59 am | — | Robert W. Baird | $219.00 | $205.35 | TheFly | Quest Diagnostics price target raised to $219 from $203 at Baird |
| February 10, 2026 7:12 pm | Tycho Peterson | Jefferies | $220.00 | $205.24 | TheFly | Quest Diagnostics price target raised to $220 from $215 at Jefferies |
| January 30, 2026 11:09 am | — | Barclays | $210.00 | $182.35 | TheFly | Quest Diagnostics upgraded to Overweight from Equal Weight at Barclays |
| October 27, 2025 10:45 am | — | Piper Sandler | $200.00 | $182.18 | TheFly | Quest Diagnostics price target raised to $200 from $190 at Piper Sandler |
| October 22, 2025 12:54 pm | — | Truist Financial | $205.00 | $184.64 | StreetInsider | Quest Diagnostics (DGX) PT Raised at Truist; '3Q Ahead As Core Trends Remain Strong' |
| October 22, 2025 12:36 pm | Erin Wright | Morgan Stanley | $207.00 | $183.18 | TheFly | Quest Diagnostics price target raised to $207 from $191 at Morgan Stanley |
Latest News for DGX
New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risks SECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory…
TORONTO--(BUSINESS WIRE)---- $DGX #Cboe--Digi Power X Inc. has graduated from the venture markets and is now listed under the symbol DGX on Cboe Canada,.
Shares of Quest Diagnostics Incorporated (NYSE: DGX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the sixteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Veteran M&A and transformation leader from Danaher and Patheon joins the Quest Diagnostics executive team SECAUCUS, N.J., Feb. 26, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot, a highly accomplished leader with more than two decades of experience in business strategy and transformation, including mergers and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.